Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 15.82 is 47% above its 5-year average of 10.78, around the middle of its 5-year range (0.85–30.14).
As of the fiscal period ended Tuesday, June 30, 2026. 11.59% below its 12-month average of 17.90.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 15.82.
QUICK RATIO (ACID-TEST)
15.82
QUICK RATIO (ACID-TEST) AVG TTM
17.90
QUICK RATIO (ACID-TEST) AVG 3Y
11.63
QUICK RATIO (ACID-TEST) AVG 5Y
10.78
QUICK RATIO (ACID-TEST) AVG 10Y
6.13
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-11.59%
CURRENT VS 3Y AVG
+36.07%
CURRENT VS 5Y AVG
+46.73%
CURRENT VS 10Y AVG
+158.13%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 571 covered companies
CURRENT VS SECTOR MEDIAN
+429.20%
vs the sector median at left
Inhibikase Therapeutics, Inc.
Market Cap
$262.75M
Quick Ratio (Acid-Test)
15.82
TTM Avg
17.90
3Y Avg
11.63
5Y Avg
10.78
Market Cap
$257.13M
Quick Ratio (Acid-Test)
3.19
TTM Avg
3.85
3Y Avg
4.21
5Y Avg
4.14
Market Cap
$260.75M
Quick Ratio (Acid-Test)
8.28
TTM Avg
3.73
3Y Avg
7.03
5Y Avg
8.20
Market Cap
$260.75M
Quick Ratio (Acid-Test)
4.46
TTM Avg
8.30
3Y Avg
6.73
5Y Avg
6.78
Market Cap
$260.03M
Quick Ratio (Acid-Test)
0.93
TTM Avg
1.36
3Y Avg
5.78
5Y Avg
8.29
Market Cap
$266.17M
Quick Ratio (Acid-Test)
16.00
TTM Avg
13.11
3Y Avg
8.33
5Y Avg
7.81
Market Cap
$255.98M
Quick Ratio (Acid-Test)
13.89
TTM Avg
8.37
3Y Avg
7.38
5Y Avg
15.00
Market Cap
$272.91M
Quick Ratio (Acid-Test)
19.48
TTM Avg
1.73
3Y Avg
4.11
5Y Avg
4.35
Market Cap
$274.71M
Quick Ratio (Acid-Test)
2.80
TTM Avg
2.74
3Y Avg
2.22
5Y Avg
2.48
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $262.75M | 15.82 | 17.90 | 11.63 | 10.78 |
| Anika Therapeutics, Inc. (ANIK)vs › | $257.13M | 3.19 | 3.85 | 4.21 | 4.14 |
| Century Therapeutics, Inc. (IPSC)vs › | $260.75M | 8.28 | 3.73 | 7.03 | 8.20 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $260.75M | 4.46 | 8.30 | 6.73 | 6.78 |
| AC Immune S.A. (ACIU)vs › | $260.03M | 0.93 | 1.36 | 5.78 | 8.29 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $266.17M | 16.00 | 13.11 | 8.33 | 7.81 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $255.98M | 13.89 | 8.37 | 7.38 | 15.00 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | 19.48 | 1.73 | 4.11 | 4.35 |
| Aurora Cannabis Inc. (ACB)vs › | $274.71M | 2.80 | 2.74 | 2.22 | 2.48 |
| Invivyd, Inc. (IVVD)vs › | $249.41M | 5.86 | 4.06 | 6.91 | 7.76 |
Quick Ratio
15.82
Excludes inventory
Current Ratio
15.82
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 15.82 |
| 2026-03-31 | 30.14 |
| 2025-12-31 | 21.70 |
| 2025-09-30 | 11.73 |
| 2025-06-30 | 10.09 |
| 2025-03-31 | 11.01 |
| 2024-12-31 | 26.37 |
| 2024-09-30 | 0.85 |
| 2024-06-30 | 2.32 |
| 2024-03-31 | 2.55 |
| 2023-12-31 | 4.13 |
| 2023-09-30 | 6.40 |
| 2023-06-30 | 8.04 |
| 2023-03-31 | 10.37 |
| 2022-12-31 | 6.59 |
| 2022-09-30 | 8.71 |
| 2022-06-30 | 7.56 |
| 2022-03-31 | 8.76 |
| 2021-12-31 | 10.47 |
| 2021-09-30 | 16.94 |
| 2021-06-30 | 25.23 |
| 2021-03-31 | 3.11 |
| 2020-12-31 | 3.13 |
| 2020-09-30 | 0.01 |
| 2020-06-30 | 0.01 |
| 2020-03-31 | 0.01 |
| 2019-12-31 | 0.01 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | 0.35 |
| 2018-03-31 | 0.13 |
| 2017-12-31 | 0.11 |
| 2017-03-31 | 0.00 |
